In the hotly patent war over the priority to the invention of the CRISPR-Cas9 system between two of the most powerful universities in the US, last week on 15 February 2017, judges at USPTO ruled in favor of the Broad Institute, MIT and declared that “there is no interference-in-fact” between the two parties.
